Please assess the completion status of the following clinical trial:

Trial Title: A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~Key Inclusion Criteria:~* Aged \>= 18 years old at the time of informed consent.~* Histologically confirmed follicular Grade 1-3a NHL.~* Relapsed or progressive disease after at least 1 prior chemotherapy requiring treatment.~* Bidimensionally measurable disease with at least 1 lesion \>= 2.0 cm in a single dimension.~* Acceptable hematologic, hepatic, and renal function parameters.~* Recovered fully from any significant toxicity associated with prior surgery, radiation treatments, chemotherapy, biological therapy, autologous bone marrow or stem cell transplant, or investigational drugs.~Key Exclusion Criteria:~* Follicular lymphoma Grade 3b.~* Rituximab refractory or refractory to anti-CD20 radioimmunotherapy (no response to prior rituximab or prior rituximab-containing regimen, or a response with a TTP of less than 6 months).~* Cancer radiotherapy, biological therapy, or chemotherapy within 3 weeks prior to Study Day 1 (6 weeks if nitrosourea or mitomycin C).~* Prior lymphoma vaccine therapy within 12 months prior to Study Day 1.~* Prior antibody therapy for lymphoma (including radioimmunotherapy) within 6 months prior to Study Day 1.~* Autologous bone marrow or stem cell transplant within 6 months prior to Study Day 1.~* Prior allogeneic transplant.~* Transfusion-dependent subjects.~* Another primary malignancy requiring active treatment (except hormonal therapy).~* Serious nonmalignant disease (e.g., congestive heart failure, hydronephrosis); active uncontrolled bacterial, viral, or fungal infections; or other conditions, which would compromise protocol objectives in the opinion of the Investigator and/or the Sponsor.~* New York Heart Association Class III or IV cardiac disease or myocardial infarction within 6 months prior to Study Day 1.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).